An oral epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer in patients with initial activating epidermal growth factor receptor mutations as well as the T790M dominant acquired resistance mutation.
Horizon Scanning
It is a challenge for health plans and clinicians to know what emerging technologies are in the preapproval phase and what their clinical, financial, and risk impacts might be. This is where we come in.The Hayes Horizon Scanning Solution identifies innovative and potentially disruptive health technologies that are in various stages of the regulatory approval process. Our Research Analysts continually investigate new technologies that are on the horizon or in the early stages of clinical investigation, as well as the testing of existing technologies that may be seeking approval for new clinical applications. Hayes Horizon Scanning helps you track emerging technologies before you need to make decisions. Accessed through the Hayes Knowledge Center, Hayes Horizon Scanning addresses the following fundamental questions to help our clients forecast emerging technologies:
- Is this emerging technology new or replacing an existing technology?
- Where is this technology in the FDA regulatory process?
- When will this technology be commercially available in the market?
- What is the projected use, cost, and financial impact of this technology?
Nuplazid (Pimavanserin)
A novel oral 5HT2A inverse agonist for the treatment of psychosis associated with Parkinson disease.
SurgiBot System
A single-port, patient-side robotic surgery system for use in laparoscopic surgery.
TOPAS (Transobturator Posterior Anal Sling) System
An implantable transobturator posterior anal sling proposed to treat women with fecal incontinence that fails to respond to more conservative treatments.
Inflectra (Formerly CT-P13; Infliximab Biosimilar)
A biosimilar to Remicade (infliximab) for treatment of adult and pediatric Crohn’s disease, adult ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis.
ETC-1002 (Bempedoic Acid)
An oral adenosine triphosphate-citrate lyase inhibitor and adenosine monophosphate-activated protein kinase activator intended for low-density lipoprotein cholesterol-lowering therapy.
ALD403 to Prevent Migraine Headache
ALD403 is a novel monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine headache prevention. CGRP is involved in vasodilation and sensory transmission and is a validated target that is believed to play a key role in migraine headache. ALD403 is administered intravenously.
Barostim neo for Drug-Resistant Hypertension
A surgically implanted device for the treatment of medically resistant hypertension that delivers chronic stimulation to baroreceptors located within the carotid sinus. Also being developed for the treatment of heart failure.
Mongersen (GED-0301) for Crohn’s Disease
An oral Smad7 antisense oligonucleotide for treatment of moderate to severe Crohn’s disease.
DIAM Spinal Stabilization System
A surgically implanted, compressible, posterior interspinous spacer for relief of low back and/or leg pain due to moderate single-level lumbar degenerative disc disease.